Pfizer Senior Director, Emerging Science Biology in Cambridge, Massachusetts
Pfizer is making significant investment in the creation of novel, first-in-class therapeutics, by combining internal discovery and validation of drug targets with external partnerships to produce clinical drug candidates for the Pfizer pipeline. This position is within the Target Sciences (TS) group, which has expertise in human genetics, functional genomics, automated analytic capabilities and data management, and target validation biology. Target Sciences works together with Pfizer's nationwide Centers for Therapeutic Innovation (CTI) within Pfizer broader External Science & Innovation group to deliver a broad and deep pipeline of drug candidates, based on emerging science in the academic world.
The primary responsibility of the newly created Emerging Science Biology team is to play a riving role in addressing the critical task, identified as a gap, of rejuvenating the WRD pipeline with innovative, differentiated FIC/ OIC programs in the years to come. This will be addressed by generation of strong data packages from target hypotheses derived from academic outreach and initiatives incl. ITENs, from human genetics, functional genomics and data mining to enable the initiation of new CTI and RU projects. This position requires deep expertise in human disease biology, a proven track record in managing target discovery and validation projects in a drug discovery setting, capability to execute, strong leadership skills, and the ability to network effectively at both a senior and hand- on level with CTI and RU biologists and Partner line scientists as well as with external academic PIs.
Key Deliverable: Bring Target Hypotheses to compelling Target Packages. Overall responsibility for designing with input from CTI, RU, PL colleagues and academics and executing target validation plans to establish equipoise data sets on prospective target discovered through the hypothesis generation engine of Target Sciences, enabling the start of novel drug discovery projects mostly in CTI.
The Head of Emerging Science Biology will work closely with the Head, Target Sciences Operations and Portfolio Integration and CTI leaders to establish an effective target validation plan review and monitoring process e.g. as operationalized through an ES&I Target Selection committee.
The emerging science biology group will play a key role in executing the plan working w/ Target Science precision editing teams and computational biologists and geneticists, with RU& CTI biologists, Med Design, BMD and academic PIs as appropriate with a particularly strong interaction with the newly established CTI China anticipated.
Lead the strategy of the Target Sciences department towards new and ongoing programs of the Centers for Therapeutic Innovation.Understand and evaluate CTI programs and identify opportunities for genetics, functional genomics, and computation to prioritize existing programs.Apply Target Sciences technologies to evaluate the selection of new drug discovery programs within CTI.Design and lead execution of studies defining confidence-in-rationale for potential drug targets and the pathway to pursue them.
Collaborate successfully within a dynamic and agile group within the broader External Science and Innovation departmental structure to produce target packages for first-in-class drug discovery programs.
PhD, postdoctoral training, and 10 years' experience in basic biology, genomics and/or pharmacology or a closely related discipline.
10 years' industrial experience using genomic, cell biological and biochemical technologies to drive drug discovery in a pharmaceutical / biotech setting.
Strong track record of execution leading target discovery and validation projects and external collaborations with external academic and biotech resources.
Excellent leadership, collaboration, communication, and organizational skills, and ability and desire to work as part of a team dedicated to innovation.
Deep knowledge of cellular and molecular biology and biochemistry and at least one human disease area, with as strong preference for immunology and oncology
Strong record of achievement as reflected in peer-reviewed publications.
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.
Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.